Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - amoxicillin trihydrate - oral capsule - 500mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - amoxicillin trihydrate - oral capsule - 500mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - amoxicillin trihydrate - oral capsule - 500mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - amoxicillin trihydrate - oral capsule - 500mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - amoxicillin trihydrate - oral capsule - 500mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 114.82 mg/ml (equivalent: amoxicillin, qty 100 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis. infections caused by pathogens with established penicillin g susceptibility should preferentially be treated with penicillin g.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin trihydrate 59 mg/ml equivalent to amoxycillin 50 mg/ml; potassium clavulanate 31.1 mg/ml equivalent to clavulanic acid 12.5 mg/ml - powder for oral suspension - active: amoxicillin trihydrate 59 mg/ml equivalent to amoxycillin 50 mg/ml potassium clavulanate 31.1 mg/ml equivalent to clavulanic acid 12.5 mg/ml excipient: aspartame butylated hydroxytoluene hydrated silica monosodium citrate passionfruit flavour 502010 ap0554 sodium benzoate sodium citrate dihydrate sorbitol xanthan gum

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg - film coated tablet - 250mg/125mg - active: amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg   potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg   excipient: colloidal silicon dioxide dimeticone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose opadry white oy-s-7300 as an alternative source of film coat sodium starch glycolate titanium dioxide - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate -